Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2008-000485-22 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder of the adult associated to a poor prognosis. MSA is clinically characterized by the association of extra-pyramidal, dysautonomic, cerebellar and pyramidal symptoms. Histological and biological studies have raised the hypothesis that, beside the well known dopamine deficiency, some of the symptoms could be related to a dysfunction in serotoninergic neurotransmission. Serotonin is involved in the modulation of several functions impaired in MSA, such as mood, motricity or sleep. The recent description of an association between loss of brainstem serotonin neurons and sudden death in patients with MSA reinforced the hypothesis of a critical role played by this neurotransmitter in the pathophysiology of this disease. Autoreceptors called 5-HT1a are strongly involved in the regulation of serotonin neurotransmission. During the last years several radio-ligands allowing in vivo PET quantification of 5-HT1a receptors, such as 18F-MPPF (4-(2'-methoxyphenyl)-1-[2'-(N-2''-piridinyl)-p-fluorobenzamide]methylpiperazine), were developed. Moreover, the investigators recently demonstrated the ability of this brain functional imaging method to investigate, in healthy volunteers, the functional properties of 5-HT1a autoreceptors through an evaluation of their desensitization after a single oral dose of fluoxetine.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Multiple system atrophy | Active Comparator |
| |
| Idiopathic Parkinson Disease | Placebo Comparator |
| |
| Volunteers without neuropsychiatric disorder (Control) | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PET (Positron Emission Tomography) Study | Radiation | 5-HT1a auto-receptors will be visualized in vivo using 18F-MPPF PET study. Two PET studies will be performed, one after the intake of a single oral dose of fluoxetine and the other after placebo. The order of fluoxetine and placebo intake will be randomly assigned. |
| Measure | Description | Time Frame |
|---|---|---|
| 18F-MPPF binding potential - Biding potential (BP) under placebo in the raphe nucleus | Amount of 5-HT1a autoreceptors (evaluated by measurement of 18F-MPPF binding potential) after intake of placebo in the raphe nucleus. | Second visit (day 1) |
| Measure | Description | Time Frame |
|---|---|---|
| 18F-MPPF binding potential - Biding potential (BP) in other brain areas | Amount of 5-HT1a autoreceptors (evaluated by measurement of 18F-MPPF binding potential) in other brain areas (brainstem, hippocampus, etc.) | Second visit (day 1) |
| Clinical parameters (motor handicap, orthostatic hypotension, quality of life, sleep, pain, tiredness) |
Not provided
Inclusion Criteria:
Patients with Multiple system atrophy (MSA)
Patients with idiopathic Parkinson's disease (IPD):
Healthy controls:
Exclusion Criteria:
Patients with Multiple system atrophy (MSA)
Patients with idiopathic Parkinson's disease
Healthy controls:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Igor SIBON, Pr | University Hospital Bordeaux (France) | Principal Investigator |
| Geneviève CHENE, Pr | University Hospital Bordeaux (France) | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Bordeaux | Bordeaux | 33076 | France | |||
| CHU Limoges |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32956556 | Result | Meyer M, Lamare F, Asselineau J, Foubert-Samier A, Mazere J, Zanotti-Fregonara P, Rizzo G, Delamarre A, Spampinato U, Rascol O, Pavy-Le Traon A, Tison F, Fernandez P, Sibon I, Meissner WG. Brain 5-HT1A Receptor Binding in Multiple System Atrophy: An [18 F]-MPPF PET Study. Mov Disord. 2021 Jan;36(1):246-251. doi: 10.1002/mds.28295. Epub 2020 Sep 21. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Brain MRI (magnetic resonance imaging) | Other | A brain MRI (magnetic resonance imaging)will be performed the day of the first PET study. |
|
| Fluoxétine / Placebo | Drug | The two PET studies will be performed, one after the intake of a single oral dose of fluoxetine and the other after placebo. The order of fluoxetine and placebo intake will be randomly assigned. |
|
| Second visit (day 1) |
| 18F-MPPF binding potential - Biding potential (BP) under placebo in other brain areas | Amount of 5-HT1a autoreceptors (evaluated by measurement of 18F-MPPF binding potential) after intake of placebo in other brain areas (brainstem, hippocampus, etc.). | Third visit (day 30) |
| 18F-MPPF binding potential - BP under fluoxetine in all brain areas | Amount of 5-HT1a autoreceptors (evaluated by measurement of 18F-MPPF binding potential - BP) after intake of fluoxetine in all brain areas. | Third visit (day 30) |
| Clinical parameters (motor handicap, orthostatic hypotension, quality of life, sleep, pain, tiredness) | Third visit (day 30) |
| Limoges |
| France |
| CHU de Toulouse | Toulouse | 31059 | France |
| ID | Term |
|---|---|
| D019578 | Multiple System Atrophy |
| ID | Term |
|---|---|
| D054969 | Primary Dysautonomias |
| D001342 | Autonomic Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C062942 | 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole |
| D009682 | Magnetic Resonance Spectroscopy |
| D005473 | Fluoxetine |
| ID | Term |
|---|---|
| D013057 | Spectrum Analysis |
| D002623 | Chemistry Techniques, Analytical |
| D008919 | Investigative Techniques |
| D011437 | Propylamines |
| D000588 | Amines |
| D009930 | Organic Chemicals |
Not provided
Not provided